Table 1.
Lidocaine (20 μM) (n=5) |
E-4031 (5 μM) (n=5) |
Quinidine (10 μM) (n=5) |
Isoproterenol (100 nM) (n=6) |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | PD- 118057 (20 μM) |
+Lidocaine | Control | PD- 118057 (20 μM) |
+E-4031 | Control | PD- 118057 (20 μM) |
+Quinidine | Control | PD- 118057 (20 μM) |
+Isoproterenol | |
APD70CT (ms) | 187±13 | 126±17* | 115±42 | 170±16 | 116±25* | 146±26† | 171±24 | 96±42* | 134±25† | 160±36 | 110±51* | 53±22† |
APD70PM (ms) | 145±12 | 100±15* | 83±12† | 154±24 | 56±27* | 96±28† | 124±20 | 45±10* | 76±10† | 137±30 | 62±27* | 22±13† |
ERP PM (ms) | 152±16 | 101±7* | 158±22† | 158±16 | 105±8* | 113±10† | 148±13 | 100±17* | 174±24† | 141±17 | 100±12* | 73±8† |
AF/AT | 0/5 | 5/5 (AF) | 1/5 (AF) 4/5 (AT) | 0/5 | 5/5 (AF) | 4/5 (AF) | 0/5 | 5/5 (AF) | 0/5 | 0/6 | 6/6 (AF) | 6/6 (AF) |
APD70: Action potential duration measured at 70% repolarization, AF: atrial fibrillation, AT: atrial tachycardia; CT: crista terminalis, ERP: effective refractory period, PM: pectinate muscle
PD-118057 vs. control; p< 0.05
Lidocaine/E-4031/Quinidine/Isoproterenol vs. PD-118057; p< 0.05